Kenneth J. O'Byrne focuses on Lung cancer, Internal medicine, Oncology, Pathology and Surgery. His Lung cancer research includes themes of Cancer research, Angiogenesis, Carcinoma and Hazard ratio. His biological study deals with issues like Gastroenterology, which deal with fields such as Neutropenia and Mucositis.
His work carried out in the field of Oncology brings together such families of science as Disease, Evidence-based medicine, Docetaxel, Nivolumab and Ipilimumab. Kenneth J. O'Byrne has researched Pathology in several fields, including Respiratory disease, Metastasis and Adenocarcinoma. His work in the fields of Surgery, such as Phases of clinical research and Performance status, overlaps with other areas such as Multicenter trial.
His primary areas of study are Internal medicine, Lung cancer, Oncology, Cancer research and Cancer. His studies deal with areas such as Gastroenterology and Surgery as well as Internal medicine. His Lung cancer research is multidisciplinary, relying on both Carcinoma, Epidermal growth factor receptor and Adenocarcinoma.
His research in Oncology tackles topics such as Nivolumab which are related to areas like Ipilimumab. Kenneth J. O'Byrne studied Cancer research and Cisplatin that intersect with Gemcitabine. His Immunology research extends to Cancer, which is thematically connected.
His primary scientific interests are in Lung cancer, Cancer research, Internal medicine, Oncology and Cancer. His Lung cancer study combines topics from a wide range of disciplines, such as Liquid biopsy, Epidermal growth factor receptor, Chemotherapy and Circulating tumor cell. The Cancer research study combines topics in areas such as Cell, Cisplatin, Cancer stem cell, non-small cell lung cancer and Biopsy.
In his work, Durvalumab is strongly intertwined with Mesothelioma, which is a subfield of Internal medicine. In Oncology, Kenneth J. O'Byrne works on issues like Immunotherapy, which are connected to Tumor microenvironment. Kenneth J. O'Byrne has included themes like Viability assay, Malignancy and Genome instability in his Cancer study.
Kenneth J. O'Byrne mainly focuses on Lung cancer, Internal medicine, Oncology, Cancer research and Circulating tumor cell. Kenneth J. O'Byrne interconnects Liquid biopsy, Chemotherapy and Epidermal growth factor receptor in the investigation of issues within Lung cancer. Many of his studies involve connections with topics such as Mesothelioma and Internal medicine.
His biological study spans a wide range of topics, including Cancer, Clinical trial, Phases of clinical research, Nivolumab and Ipilimumab. His research in Clinical trial intersects with topics in Carcinoma and Docetaxel. His research integrates issues of DNA, DNA damage, DNA repair, Anaplastic lymphoma kinase and Biopsy in his study of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto.
The New England Journal of Medicine (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist;James Chih-Hsin Yang;Nobuyuki Yamamoto;Kenneth John O'Byrne.
Journal of Clinical Oncology (2013)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D. Hellmann;Tudor-Eliade Ciuleanu;Adam Pluzanski;Jong Seok Lee.
The New England Journal of Medicine (2018)
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
Michael Marty;Francesco Cognetti;Dominique Maraninchi;Raymond Snyder.
Journal of Clinical Oncology (2005)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Robert Pirker;Jose R. Pereira;Aleksandra Szczesna;Joachim von Pawel.
The Lancet (2009)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski.
The New England Journal of Medicine (2019)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian.
Lancet Oncology (2015)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang.
Lancet Oncology (2016)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker;Jose R. Pereira;Joachim Von Pawel;Maciej Krzakowski.
Lancet Oncology (2012)
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies
Bruno Morgan;Anne L. Thomas;Joachim Drevs;Juergen Hennig.
Journal of Clinical Oncology (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: